Yahoo Finance

Needham analyst David Saxon raised the firm’s price target on iRhythm (IRTC) to $125 from $112 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note.

Invest with Confidence:

• Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.

• Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on IRTC:

• iRhythm Technologies Reports Strong Growth and Innovation

• iRhythm sees FY24 revenue slightly above high end of previous guidance range

• iRhythm price target raised to $120 from $105 at Oppenheimer

• iRhythm price target raised to $111 from $85 at Truist

• iRhythm price target raised to $152 from $125 at Canaccord